Skylands Capital LLC Sells 44,894 Shares of Haemonetics Corporation $HAE

Key Points

• Skylands Capital LLC cut its stake in Haemonetics by 55.2%, selling 44,894 shares in Q4 and now holds 36,475 shares (about 0.08% of the company) valued at $2.923 million; institutional investors own 99.67% of the stock.
• Haemonetics beat last quarter's expectations with EPS of $1.31 (vs. $1.27 expected) and revenue of $338.97 million (vs. $331.90 million), and set FY2026 guidance at 4.900–5.000 EPS (sell-side forecast ~4.95).
• Shares opened at $60.52 (1‑year range $47.31–$87.32) with a market cap of $2.81 billion; analysts' consensus is a Moderate Buy with an average target of $82.78 amid mixed price-target revisions.

Skylands Capital LLC cut its stake in Haemonetics Corporation (NYSE:HAE - Free Report) by 55.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 36,475 shares of the medical instruments supplier's stock after selling 44,894 shares during the quarter. Skylands Capital LLC owned about 0.08% of Haemonetics worth $2,923,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Haemonetics by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier's stock worth $1,877,000 after purchasing an additional 971 shares during the period. Caxton Associates LLP purchased a new stake in shares of Haemonetics in the first quarter worth about $216,000. United Services Automobile Association purchased a new stake in shares of Haemonetics in the first quarter worth about $212,000. Empowered Funds LLC boosted its position in shares of Haemonetics by 9.1% in the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier's stock valued at $283,000 after acquiring an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier's stock valued at $9,923,000 after acquiring an additional 9,051 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Trading Up 1.0%

Shares of HAE opened at $60.52 on Tuesday. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $87.32. The company has a market capitalization of $2.81 billion, a P/E ratio of 16.67, a P/E/G ratio of 1.17 and a beta of 0.36. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. The firm's 50 day simple moving average is $59.98 and its 200 day simple moving average is $66.37.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. The business had revenue of $338.97 million during the quarter, compared to analysts' expectations of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business's quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Sell-side analysts forecast that Haemonetics Corporation will post 4.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on HAE shares. Robert W. Baird set a $81.00 target price on shares of Haemonetics in a report on Friday, February 6th. Weiss Ratings restated a "hold (c)" rating on shares of Haemonetics in a research report on Monday, December 29th. Mizuho decreased their price target on shares of Haemonetics from $80.00 to $70.00 and set an "outperform" rating on the stock in a report on Monday, April 13th. Wall Street Zen upgraded Haemonetics from a "hold" rating to a "buy" rating in a research report on Saturday, January 10th. Finally, Citigroup dropped their price objective on Haemonetics from $75.00 to $70.00 and set a "neutral" rating for the company in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Haemonetics currently has a consensus rating of "Moderate Buy" and an average target price of $82.78.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.